Dr. Wenxin Liu 刘文欣
Chief Physician
Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis, surgery, and individualized comprehensive treatment for benign and malignant gynecologic tumors, including cervical, endometrial, ovarian, fallopian tube, vulvovaginal, and urethral cancers.
Dr. Liu holds a doctorate in oncology. Expertise includes complex surgeries, cytoreductive surgery, systematic lymph node dissection, robotic and laparoscopic minimally invasive procedures, colposcopy, and hysteroscopy. Experience covers individualized comprehensive care combining surgery with radiotherapy, chemotherapy, targeted therapy, interventional therapy, and immunotherapy, guided by molecular diagnosis and prognosis monitoring.
Professional roles
- Member, Tianjin Branch of the Chinese Medical Association
- Member, Gynecologic Oncology Professional Committee, China Anti-Cancer Association
- Member, Obstetrics and Gynecology Professional Committee, Robotics Branch, Chinese Medical Doctor Association
- Member, Smart Healthcare Professional Committee, China Health Promotion Association
Name order: in Chinese the family name comes first (Liu Wenxin). Papers usually list the name as Wenxin Liu or Liu W.
Selected publications
26 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Onco Targets Ther, 2025 (first author): Real-World Experience of Niraparib as Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer: A Single-Center Retrospective Study. PubMed 41185856
- Signal Transduct Target Ther, 2025 (senior author): Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study. PubMed 40615377
- Cancer Treat Res Commun, 2025 (senior author): Clonal origins and divergent evolutionary relationships of synchronous multiple malignant neoplasms in gynecology revealed by next-generation sequencing. PubMed 41061386
- Cancer Med, 2024 (senior author): Cervical cancer-specific long non-coding RNA landscape reveals the favorable prognosis predictive performance of an ion-channel-related signature model. PubMed 38864475
- Gland Surg, 2023 (senior author): A case series on the efficacy and safety of a PD-1 inhibitor combined with antiangiogenic agents in the treatment of recurrent MSI-H endometrial cancer. PubMed 37701298
- Int J Nanomedicine, 2021 (senior author): Combination of Chemotherapy and Photodynamic Therapy with Oxygen Self-Supply in the Form of Mutual Assistance for Cancer Therapy. PubMed 34093012
- Front Immunol, 2019 (senior author): Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition. PubMed 31105696
- Cancer Biol Med, 2018 (senior author): LncRNA PVT1 promotes ovarian cancer progression by silencing miR-214. PubMed 30197791
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion